8 completed, 5 recruiting, 5 unknown, 3 not yet recruiting. 7 Phase 2, 6 Phase 4, 4 Not applicable, 4 Phase 1, 4 Phase 3.
Follow nafamostat: new trials by email Literature Review of nafamostat trials Research Report on nafamostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury Citrate anticoagulation, Nafamostat Mesylate - Sepsis, Acute Kidney Injury | Phase 4 | Not yet recruiting | Jianfeng Xie | 1162 | 2026-06-10 | 2026-06-03 |
| Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU) Nafamostat Low-Dose Group, Nafamostat High-Dose Group - Continuous Renal Replacement Therapy (CRRT) | Phase 2 | Recruiting | Zhujiang Hospital | 92 | 2026-04-07 | 2026-04-14 |
| The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration Nafamostat Mesylate, sodium citrate - Sepsis-induced Coagulopathy (SIC) | Not applicable | Not yet recruiting | The First Hospital of Jilin University | 282 | 2025-07-01 | 2025-05-29 |
| A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation Nafamostat, Heparin - ECMO | Not applicable | Recruiting | Beijing Chao Yang Hospital | 140 | 2025-05-10 | 2026-09-09 |
| Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102) PF614 capsule, Nafamostat Mesylate - Pharmacokinetics, Healthy Volunteer | Phase 1 | Recruiting | Ensysce Biosciences | 54 | 2024-11-24 | 2026-05-26 |
| Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO nafamostat mesilate, unfractionated heparin group - Extracorporeal Membrane Oxygenation Complication | Not applicable | Recruiting | Xiaotong Hou | 80 | 2024-07-01 | 2025-09-25 |
| Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI Nafamostat Mesylate, Unfractionated Heparin - Sepsis | Phase 4 | Not yet recruiting | Shen Lei | 156 | 2024-04-01 | 2024-04-19 |
| The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study Nafamostat Mesylate - Dialysis; Complications, Bleeding | Not applicable | Recruiting | Wonju Severance Christian Hospital | 100 | 2023-12-01 | 2024-07-30 |
| Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy Nafamostat mesilate, 5% glucose - Sepsis, Sepsis-induced Coagulopathy | Phase 4 | Unknown | Xu Li | 778 | 2023-10-01 | 2023-10-12 |
| Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation Nafamostat Mesylate, Unfractionated Heparin - Critical Illness, Anticoagulation | Phase 2 | Unknown | Xiaobo Yang, MD | 40 | 2022-12-20 | 2023-02-15 |
| Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101) PF614 solution, Naltrexone Hydrochloride, Nafamostat Mesylate - Pharmacokinetics | Phase 1 | Completed | Ensysce Biosciences | 111 | 2021-12-01 | 2024-09-24 |
| Efficacy of Nafamostat in Covid-19 Patients (RACONA Study) Nafamostat Mesilate, Placebo - COVID19 | Phase 2 / Phase 3 | Unknown | University Hospital Padova | 256 | 2021-06-04 | 2023-11-01 |
| A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia Nafamostat Mesilate - COVID-19 | Phase 2 | Completed | Chong Kun Dang Pharmaceutical | 13 | 2020-12-21 | 2021-08-13 |
| A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia Nafamostat Mesilate - COVID-19 | Phase 2 | Completed | Chong Kun Dang Pharmaceutical | 104 | 2020-09-25 | 2021-02-02 |
| Oral Nafamostat in Healthy Volunteers (NAF-101) Nafamostat Mesilate, Placebo - Pharmacokinetics | Phase 1 | Completed | Ensysce Biosciences | 17 | 2020-09-21 | 2024-09-24 |
| Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal Nafamostat Mesilate - COVID-19 | Phase 3 | Terminated | Institut Pasteur de Dakar | 59 | 2020-08-13 | 2024-06-21 |
| Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (Arm Closed) Nafamostat Mesilate, (Arm Closed) Enoxaparin, (Arm Closed) Dalteparin - SARS-CoV-2 Infection (COVID-19) | Phase 3 | Unknown | University of Melbourne | 2200 | 2020-07-28 | 2024-05-16 |
| DEFINE - Evaluating Therapies for COVID-19 Nafamostat Mesilate, TD139, Standard care - COVID-19 | Phase 1 / Phase 2 | Completed | University of Edinburgh | 71 | 2020-07-03 | 2025-08-07 |
| Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia Nafamostat Mesylate - Corona Virus Infection, COVID-19 | Phase 2 / Phase 3 | Unknown | Gyeongsang National University Hospital | 84 | 2020-06-10 | 2020-06-09 |
| Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy Nafamostat mesilate, Normal saline - Acute Kidney Injury | Phase 4 | Completed | Kyungpook National University Hospital | 60 | 2010-07-01 | 2015-06-23 |
Showing 20 of 22. Sign in to see all of them.
COVID-19 (7) · Acute Kidney Injury (4) · Sepsis (3) · Coronavirus Infections (2) · Critical Illness (1) · Hemorrhage (1) · Pneumonia (1)
Ensysce Biosciences (3) · Chong Kun Dang Pharmaceutical (2) · Beijing Chao Yang Hospital (1) · Gyeongsang National University Hospital (1) · Institut Pasteur de Dakar (1) · Jianfeng Xie (1) · Kyungpook National University Hospital (1) · Seoul National University Hospital (1) · Shen Lei (1) · The First Hospital of Jilin University (1) · University Hospital Padova (1) · University of Edinburgh (1) · University of Melbourne (1) · Wonju Severance Christian Hospital (1) · Xiaobo Yang, MD (1)
China (5) · South Korea (4) · United States (3) · Australia (1) · Italy (1) · Russia (1) · Senegal (1) · United Kingdom (1)
Jeffrey Levy, MD, PhD (2) · Amadou A. Sall, PhD (1) · Bing Sun, MD (1) · Chan-Duck Kim, M.D., PhD (1) · Dongho Kim, MD (1) · Fabien Taieb, MD, PhD (1) · Gian Paolo Rossi, Prof. (1) · Kev Dhaliwal (1) · Lei Shen, MD (1) · Moussa Seydi, MD (1) · Steven Tong, Prof (1) · William K Schmidt, PhD (1) · Xu Li, Phd (1) · Yingzi Huang (1)
PMID 32142651, PMID 33314078, PMID 11594901, PMID 25302581, PMID 25822153, PMID 27550352, PMID 30536180, PMID 32171076, PMID 32187464, PMID 32312781, PMID 33502773, PMID 34473343, PMID 34723164, PMID 34814935, PMID 34953516, PMID 35152152, PMID 35244208, PMID 35972987, PMID 36514143, PMID 38189593, PMID 38320033, PMID 38320527, PMID 40731293
5UH3DA047682-04 (1), UG3DA047682-02 (1)